Journal of Peking University (Health Sciences) ›› 2020, Vol. 52 ›› Issue (5): 919-923. doi: 10.19723/j.issn.1671-167X.2020.05.021

Previous Articles     Next Articles

125I seed brachytherapy for recurrent salivary gland carcinoma after external radiotherapy

Huan-bin YU,Wen-jie WU,Xiao-ming LV,Yan SHI,Lei ZHENG,Jian-guo ZHANG()   

  1. Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China
  • Received:2018-09-27 Online:2020-10-18 Published:2020-10-15
  • Contact: Jian-guo ZHANG E-mail:rszhang@126.com

Abstract:

Objective: To investigate the clinical application and efficacy of 125I radioactive seeds implantation in the treatment of recurrent salivary gland carcinoma after external radiotherapy. Methods: From July 2004 to July 2016, 43 cases of recurrent salivary gland carcinoma of the neck after external radiotherapy or surgery combined with external radiotherapy were treated. According to the conventional segmentation radiotherapy for head and neck cancer (once a day, 1.8-2.0 Gy each time, 5 days per week), the cumulative radiation dose of the patients in this group was calculated. In the study, 26 patients received 50-60 Gy, 7 patients received less than 50 Gy, 4 patients received 60-70 Gy, and 6 patients received more than 80 Gy (range: 80-120 Gy). The interval between the last external irradiation and local recurrence was 4-204 months, and the median interval was 48 months. Among them, 25 cases were treated with 125I radioactive seeds implantation only and 18 cases were treated with 125I radioactive seeds implantation after operation. The prescription dose was 100-140 Gy. The control rate, survival rate and disease-free survival rate were recorded to evaluate the side effects. Results: The median follow-up time was 27 months (ranging from 2.5 to 149.0 months). Among them, the median follow-up time of adenoid cystic carcinoma patients was 31 months (range: 2.5-112.0 months), and the median follow-up time of mucoepidermoid carcinoma patients was 18 months (range: 5-149 months). The local control rates for 1, 3 and 5 years were 66.5%, 48.8% and 42.7%, respectively. The 1-, 3- and 5- year survival rates were 88.0%, 56.7% and 45.8%, respectively. The disease-free survival rates of 1, 3 and 5 years were 58.3%, 45.4% and 38.1%, respectively. There was no statistically significant difference in local control rate, survival rate, and disease-free survival between the radioactive seeds implantation group and the radioactive seeds implantation group after surgical resection. There were 2 cases of acute radiation reaction Ⅰ/Ⅱ and 3 cases of reaction Ⅲ or above. In the late stage of radiotherapy, there were 8 cases with Ⅰ/Ⅱ grade reaction and 3 cases with Ⅲ grade or above reaction. The incidence of radiation reactions of Grade Ⅲ and above was 7%. Conclusion: 125I radioactive seeds implantation provides an alternative method for the treatment of recurrent salivary gland carcinoma after external radiotherapy. The local control rate and survival rate are improved on the premise of low incidence of side effects.

Key words: Salivary gland neoplasms, Neoplasm recurrence, local, Brachytherapy

CLC Number: 

  • R739.84

Figure 1

Local control rate"

Figure 2

Local control rate for two methods"

Figure 3

Overall survival rate"

Figure 4

Overall survival rate for two methods"

Figure 5

Disease-free survival rate"

Figure 6

Disease-free survival rate for two methods"

[1] Adelstein DJ, Koyfman SA, El-Naggar AK, et al. Biology and management of salivary gland cancers[J]. Semin Radiat Oncol, 2012,22(3):245-253.
pmid: 22687949
[2] Zbaren P, Nuyens M, Caversaccio M, et al. Postoperative radiation therapy for T1 and T2 primary parotid carcinoma: Is it useful?[J]. Otolaryngol Head Neck Surg, 2006,135(1):140-143.
pmid: 16815199
[3] Terhaard CH, Lubsen H, Rasch CR, et al. The role of radiotherapy in the treatment of malignant salivary gland tumors[J]. Int J Radiat Oncol Biol Phys, 2005,61(1):103-111.
pmid: 15629600
[4] Chen AM, Garcia J, Bucci MK, et al. Recurrent salivary gland carcinomas treated by surgery with or without intraoperative radiation therapy[J]. Head Neck, 2008,30(1):2-9.
doi: 10.1002/(ISSN)1097-0347
[5] 甄鹏, 张学峰, 兰丽君, 等. 放射性125I粒子植入治疗颈部淋巴转移癌放疗后复发 [J]. 中华临床医师杂志: 电子版, 2010,4(6):810-813.
[6] Garden AS, Weber RS, Morrison WH, et al. The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation[J]. Int J Radiat Oncol Biol Phys, 1995,32(3):619-626.
pmid: 7790247
[7] Wong SJ, Machtay M, Li Y. Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone?[J]. J Clin Oncol, 2006,24(17):2653-2658.
pmid: 16763279
[8] Locati LD, Perrone F, Cortelazzi B, et al. A phase Ⅱ study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact[J]. Eur J Cancer, 2016(69):158-165.
[9] Hotte SJ, Winquist EW, Lamont E, et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase Ⅱ consortium study[J]. J Clin Oncol, 2005,23(3):585-590.
doi: 10.1200/JCO.2005.06.125 pmid: 15659505
[10] Pederson AW, Haraf DJ, Blair EA, et al. Chemoreirradiation for recurrent salivary gland malignancies[J]. Radiother Oncol, 2010,95(3):308-311.
doi: 10.1016/j.radonc.2010.03.006 pmid: 20385414
[11] Douglas JG, Koh WJ, Austin-Seymour M, et al. Treatment of salivary gland neoplasms with fast neutron radiotherapy[J]. Arch Otolaryngol Head Neck Surg, 2003,129(9):944-948.
doi: 10.1001/archotol.129.9.944 pmid: 12975266
[12] Lee N, Millender LE, Larson DA, et al. Gamma knife radiosurgery for recurrent salivary gland malignancies involving the base of skull[J]. Head Neck, 2003,25(3):210-216.
pmid: 12599288
[13] Salama JK, Vokes EE, Chmura SJ, et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma[J]. Int J Radiat Oncol Biol Phys, 2006,64(2):382-391.
pmid: 16213104
[14] Lee N, Chan K, Bekelman JE, et al. Salvage re-irradiation for recurrent head and neck cancer[J]. Int J Radiat Oncol Biol Phys, 2007,68(3):731-740.
pmid: 17379449
[15] Haraf DJ, Weichselbaum RR, Vokes EE. Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: A potentially curable disease[J]. Ann Oncol, 1996,7(9):913-918.
pmid: 9006741
[16] Ohizumi Y, Tamai Y, Imamiya S, et al. Prognostic factors of reirradiation for recurrent head and neck cancer[J]. Am J Clin Oncol, 2002,25(4):408-413.
pmid: 12151975
[17] Park RI, Liberman FZ, Lee DJ, et al. Iodine-125 seed implantation as an adjunct to surgery in advanced recurrent squamous cell cancer of the head and neck[J]. Laryngoscope, 1991,101(4 Pt 1):405-410.
pmid: 1895857
[18] 江萍, 马月, 王俊杰, 等. 超声引导放射性125I粒子植入治疗头颈部复发肿瘤 [J]. 北京大学学报(医学版), 2012,44(2):291-294.
[19] Zheng L, Zhang J, Zhang J, et al. Preliminary results of 125I interstitial brachytherapy for locally recurrent parotid gland cancer in previously irradiated patients [J]. Head Neck, 2012,34(10):1445-1449.
doi: 10.1002/hed.21955 pmid: 22488812
[1] XIAO Ruo-tao,LIU Cheng,XU Chu-xiao,HE Wei,MA Lu-lin. Prognostic value of preoperative platelet parameters in locally advanced renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 647-652.
[2] Hong-quan QIN,You ZHENG,Man-na WANG,Zheng-rong ZHANG,Zu-biao NIU,Li MA,Qiang SUN,Hong-yan Huang,Xiao-ning WANG. Subcellular localization of GTPase of immunity-associated protein 2 [J]. Journal of Peking University (Health Sciences), 2020, 52(2): 221-226.
[3] Xu-chu ZHANG,Jian-hua ZHANG,Rong-fu WANG,Yan FAN,Zhan-li FU,Ping YAN,Guang-yu ZHAO,Yan-xia BAI. Diagnostic value of 18F-FDG PET/CT and tumor markers (CEA, CA19-9, CA24-2) in recurrence and metastasis of postoperative colorectal moderately differentiated adenocarcinoma [J]. Journal of Peking University(Health Sciences), 2019, 51(6): 1071-1077.
[4] Cong LI,Shu-ming LIU,Lei ZHENG,Ming-wei HUANG,Yan SHI,Xiao-ming LV,Jian-guo ZHANG,Jie ZHANG. Study of surgery combined with 125I brachytherapy for adenoid cystic carcinoma of oral and maxillofacial region [J]. Journal of Peking University(Health Sciences), 2019, 51(1): 49-52.
[5] YE Ke-qiang, HUANG Ming-wei, LI Jun-li, TANG Jin-tian, ZHANG Jian-guo. Simulation of dose distribution in bone medium of 125I photon emitting source with Monte Carlo method [J]. Journal of Peking University(Health Sciences), 2018, 50(1): 131-135.
[6] WANG Wei, ZHENG Lei, LIU Shu-ming, HUANG Ming-wei, SHI Yan, LV Xiao-ming, ZHANG Jie, ZHANG Jian-guo. Distant metastases of malignant salivary gland carcinoma after treated by 125Ⅰinternal brachy therapy alone [J]. Journal of Peking University(Health Sciences), 2017, 49(3): 547-550.
[7] GUO Fu-xin, JIANG Yu-liang, JI Zhe, PENG Ran, SUN Hai-tao, WANG Jun-jie. 3D printed template-assisted and computed tomography image-guided 125-iodine seed implantation for supraclavicular metastatic tumor: a dosimetric study [J]. Journal of Peking University(Health Sciences), 2017, 49(3): 506-511.
[8] XU Ting, LI Min, TIAN Yang, SONG Jin-tao, NI Cheng, GUO Xiang-yang. Clinical evaluation of in-plane ultrasound-guided thoracic paravertebral block using laterally intercostal approach [J]. Journal of Peking University(Health Sciences), 2017, 49(1): 148-152.
[9] XING Yun-chao, XIONG Geng-yan, FANG Dong, ZHANG Zheng, CAI Lin, ZHANG Lei, HE Zhi-song, LI Xue-song, ZHOU Li-qun. Preoperative prognostic factors and preoperative risk stratification of upper tract urothelial carcinoma [J]. Journal of Peking University(Health Sciences), 2016, 48(6): 1032-1037.
[10] ZHANG Feng-Bo, DU Yuan, SHAO Qiang, TIAN Ye. Treatment of local low/intermediate risk prostate cancer with low dose rate brachytherapy: a report of 133 cases at a single center [J]. Journal of Peking University(Health Sciences), 2015, 47(4): 611-614.
[11] LIU Yu-Qing, LU Jian, ZHAO Lei, HOU Xiao-Fei, MA Lu-Lin. Prognostic factors for intravesical recurrence after surgery for upper tract urothelial carcinoma in renal transplant recipients [J]. Journal of Peking University(Health Sciences), 2015, 47(4): 605-610.
[12] WANG Wei, ZHENG Lei, LIU Shu-Ming, HUANG Ming-Wei, SHI Yan, LV Xiao-Ming , ZHANG Jie, ZHANG Jian-Guo. Clinical investigation on distant metastases of salivary gland carcinoma after being treated by surgery combined with 125I internal brachytherapy [J]. Journal of Peking University(Health Sciences), 2015, 47(3): 504-508.
[13] YU Guang-Yan, MA Da-Quan. Fifty years’ retrospection of systemic study on salivary gland tumors [J]. Journal of Peking University(Health Sciences), 2015, 47(1): 1-7.
[14] YANG Yang, XIAO Yun-Xiang, ZHOU Li-Qun, HE Zhi-Song, JIN Jie. Long-term outcome of isolated local recurrence following radical nephrectomy [J]. Journal of Peking University(Health Sciences), 2014, 46(4): 528-531.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] . [J]. Journal of Peking University(Health Sciences), 2009, 41(3): 376 -379 .
[2] . [J]. Journal of Peking University(Health Sciences), 2009, 41(4): 459 -462 .
[3] . [J]. Journal of Peking University(Health Sciences), 2010, 42(1): 82 -84 .
[4] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 319 -322 .
[5] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 333 -336 .
[6] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 337 -340 .
[7] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 225 -328 .
[8] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 346 -350 .
[9] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 351 -354 .
[10] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 369 -373 .